Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-2064

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-2064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636292064)

This text provides instructions and information for the NILD Rivastigmine Transdermal System. Each system contains 27 mg of Rivastigmine and provides 13.3 mg every 24 hours. It is recommended to store the system at 25°C, and one patch should be worn at a time and changed every 24 hours. The patch should be applied to intact skin and should not be cut. Additionally, the patch should be kept out of reach of children and is for transdermal use only. The text also includes the NDC code and branding information for the product.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

FDA Label Image

Figure 1 (Rivastigmine 02)

Layer 1, Layer 2, Layer 3, and Layerd are mentioned, along with the repeated word "Dimple." No further information is available to provide a useful description.*

FDA Label Image

Figure 2 (Rivastigmine 03)

The text represents the concentration of Rivastigmine in ng/mL for three groups with different dosages: 13.3 mg/24 hours (n = 19), 9.5 mg/24 hours (n = 22), and 4.6mg/24 hours (n = 22). There is no other information available in the text.*

FDA Label Image

Figure 3 (Rivastigmine 04)

FDA Label Image

Figure 4 (Rivastigmine 05)

FDA Label Image

Figure 5 (Rivastigmine 06)

FDA Label Image

Figure 6 (Rivastigmine 07)

FDA Label Image

Figure 7 (Rivastigmine 08)

The text appears to be reporting the results of a study on the effectiveness of a medication called Rivastigmine Transdermal System. The table shows LS mean differences and improvement percentages for weeks 8, 16, and 24 of treatment, along with p-values indicating statistical significance. The medication was tested using two different dosages: 15 cm² and 5 cm².*

FDA Label Image

Figure 8 (Rivastigmine 09)

This is a brief report of clinical trial results comparing the 5 and 15 cm² patches of the Rivastigmine Transdermal System after 8, 16, and 24 weeks of treatment. The analysis is based on LS means and their standard errors using a statistical model adjusted for pooled center and baseline measurements. The table shows the LS mean improvements in the cognitive function scores and their corresponding p-values, which suggest a significant difference only for the 16 weeks follow-up time.*

FDA Label Image

Figure A (Rivastigmine 10)

FDA Label Image

Figure B (Rivastigmine 11)

FDA Label Image

Figure C (Rivastigmine 12)

FDA Label Image

Figure D (Rivastigmine 13)

Protective liners are typically used to cover and protect surfaces from damage, scratches or contamination. The given text seems to only contain partial words and is not available for generating a meaningful description.*

FDA Label Image

Figure E (Rivastigmine 14)

FDA Label Image

Figure F (Rivastigmine 15)

FDA Label Image

Figure G (Rivastigmine 16)

FDA Label Image

Figure H (Rivastigmine 17)

This text provides instructions for disposing of a slide folded patch. It advises folding the sticky sides of the patch together and placing it in the trash. The text also recommends keeping the folded patch away from children and pets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.